Project description:Gene expression analysis of four different treatments of Aspergillus nidulans. reference line (A.nidulans), line A (A.nidulans + Streptomyces rapamycinicus), line B (A.nidulans + orsellinic acid), line C (A.nidulans + lecanoric acid)
Project description:Streptomyces rapamycinicus NRRL 5491 is a well-known producer of rapamycin, a secondary metabolite with useful bioactivities, including antifungal, antitumor, and immunosuppressive functions. For the enhanced rapamycin production, a rapamycin-overproducing strain SRMK07 was previously obtained as a result of random mutagenesis. To identify genomic changes that allowed the SRMK07 strain's enhanced rapamycin production, genomes of the NRRL 5491 and SRMK07 strains were newly sequenced in this study. The resulting genome sequences of the wild-type and SRMK07 strains showed the size of 12.47 Mbp and 9.56 Mbp, respectively. Large deletions were observed at both end regions of the SRMK07 strain's genome, which cover 17 biosynthetic gene clusters (BGCs) encoding secondary metabolites. Also, genes in a genomic region containing the rapamycin BGC were shown to be duplicated. Finally, comparative metabolic network analysis using these two strains' genome-scale metabolic models revealed biochemical reactions with different metabolic fluxes, which were all associated with NADPH generation. Taken together, the genomic and computational approaches undertaken in this study suggest biological clues for the enhanced rapamycin production of the SRMK07 strain. These clues can also serve as a basis for systematic engineering of a production host for further enhanced rapamycin production.
Project description:Streptomyces rapamycinicus strain NRRL 5491 produces the important drug rapamycin. It has a large genome of 12.7 Mb, of which over 3 Mb consists of 48 secondary metabolite biosynthesis clusters.
Project description:Gene expression analysis of four different treatments of Aspergillus nidulans. reference line (A.nidulans), line A (A.nidulans + Streptomyces rapamycinicus), line B (A.nidulans + orsellinic acid), line C (A.nidulans + lecanoric acid) For each of these treatments 2 biological replicates were made.
Project description:Aspergillus nidulans competes in its natural environment with other microorganisms. It has been known that the bacterium Streptomyces rapamycinicus induces the production of Orsellinic acid in A. nidulans and we found that the major trigger of this induction is Polaramycin B produced by S. rapamycinicus. Here we show the transcriptome of A. nidulans following treatment with 0.5µg/ml Polaramycin B after 30 minutes and 3 hours.
